||NCI director Dr. John Niederhuber (r) welcomes new NCAB members. They are (front row, from l) Dr. Karen Dow Meneses, Robert A. Ingram, Dr. Carolyn D. Runowicz. In the second row are (from l) Dr. Lloyd K. Everson, Dr. Bruce A. Chabner and Dr. Donald S. Coffey.
The White House recently announced the appointment of seven new members to the National Cancer Advisory Board and the designation
of a new NCAB chairperson. They are:
Chairperson Dr. Carolyn D. Runowicz is director,
Carole and Ray Neag Comprehensive Cancer
Center, Northeast Utilities chair in experimental
oncology and professor of obstetrics and gynecology, division of gynecologic oncology,
University of Connecticut Health Center.
She is a nationally prominent expert in gynecologic cancers and women’s health and is involved in many national health organizations and professional societies.
|Below are Dr. Anthony Atala (top) and Dr. Judah Folkman.
Dr. Anthony Atala is W.H. Boyce professor and director of the Wake Forest Institute for Regenerative
Medicine and chair of the department of urology, Wake Forest University School of Medicine.
His research in regenerative medicine and tissue engineering focuses on growing numerous
new human tissues and organs to repair or replace those damaged by age, cancer, trauma or abnormal development.
Dr. Bruce A. Chabner is chief, hematology/oncology, clinical director, Massachusetts General Hospital Cancer Center, professor of medicine at Harvard Medical School and previous
director of NCI’s former Division of Cancer
Treatment from 1982-1995. He has a special
interest in the treatment of lymphoma, with a focus on experimental new drugs, particularly
natural products and signal-transduction
Dr. Donald S. Coffey is Catherine Iola and J. Smith Michael distinguished professor of urology,
Johns Hopkins University School of Medicine.
His research includes the role of the nuclear
matrix in oncogenesis and the mechanism of action of androgens in inducing prostate growth and gene function during duplication of DNA and the development of cancer.
Dr. Lloyd K. Everson is vice chairman and member of the board of directors, US Oncology Inc. He works with oncologists across the country
to advance the quality of care available to cancer patients.
Dr. Judah Folkman is Julia Dyckman Andrus professor of pediatric surgery at Harvard Medical
School and director, Vascular Biology Program,
Boston Children’s Hospital. His research has been instrumental in the discovery that tumor growth is dependent on angiogenesis, which has led to the treatment of invasive, malignant cancers and has resulted in numerous
clinical trials with treatments also applied to benign diseases such as psoriasis and macular
Robert A. Ingram is vice chairman of pharmaceuticals,
GlaxoSmithKline and former chairman
and chief executive officer of Glaxo Wellcome.
He has served on the boards of numerous community and civic organizations such as the board of advisors for the Forum for Corporate Conscience, which advocates socially, economically
and environmentally responsible, values-based business leadership.
Dr. Karen Dow Meneses is professor, Beat M. & Jill L. Kahli endowed chair in oncology nursing,
University of Central Florida. Her main research interests are in breast cancer, quality
of life and cancer survivorship, screening and early detection of cancer and in skin cancer prevention for adolescents for which she has received numerous honors.